Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal DOI Creative Commons
Ty S. Schepis

Addiction, Год журнала: 2024, Номер unknown

Опубликована: Дек. 10, 2024

While awaiting randomized controlled trial results, analyses of electronic heath record data can further our understanding the effectiveness glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists for substance use disorders without medication treatment options, such as cannabis stimulant disorders. Many efficacious behavioral treatments exist (SUDs), but these often have important limitations. Behavioral options that include cognitive–behavioral therapy contingency management effectively treat a variety SUDs [1, 2], interventions are limited by their expense, availability trained clinicians motivation time commitment required those seeking [3, 4]. SUD medications similarly impacted access, cost motivational barriers [3], with structural in some countries [5, 6] resulting from unique concerns about potential misuse or diversion highly effective opioid agonist [7]. Along limitations, many individuals may not benefit specific treatment, highlighting need ongoing development. Qeadan et al. [8] provide intriguing evidence linked to reduced incidence alcohol intoxication overdose disorder disorder, respectively. Using health (EHR) US sample, they found 50% reduction medical visits 40% overdose. When combined animal [9] emerging more mixed human experimental observational studies [10-12], al.'s methodological perspective strengthens case double-blind, trials (RCTs) evaluate SUD. Indeed, diverse sets methodologies samples support GIP GLP-1 increase RCTs, addictions research needs perspectives truly understand causes develop Medication alcohol, nicotine/tobacco dependence be reasons noted above, at least exist. This is disorders, where no approved available [13-15]. Thus, clear direction future test efficacy psychostimulant ultimate standard will double-blind researchers should also consider using administrative outcomes Together re-analysis existing study data, rapid evaluation EHR motivate inform design RCTs ultimately determine utility cannabis, other SUDs. In addition evaluations GIP-1 offer rich opportunity reuse past, only very perceptive could identify promising repurposing SUD, exponential increases computing power newer machine-learning artificial intelligence methods, opportunities large-scale exploratory investigations candidates later hypothesis-driven evaluation. Ultimately, caution needed when approaching Leggio [16] highlighted. Regulatory approval necessary step before any [16], meantime investigate exploration large therapies move forward advance scope Ty S. Schepis: Conceptualization; funding acquisition; writing - original draft. article was funded Department Health Human Services, National Institutes Health, Institute on Drug Abuse (R01DA043691). T.S.S. receives Abuse, Substance Mental Services Administration Food Administration.

Язык: Английский

Socio-ecological Determinants of Detectable Viremia among Pregnant People Living with HIV in South Brazil: The Role of Stimulant Use Disorder and Homelessness DOI Creative Commons
Christopher J. Hernandez,

Fernando Echegaray,

Kavya G. Sundar

и другие.

AIDS and Behavior, Год журнала: 2025, Номер unknown

Опубликована: Фев. 3, 2025

Язык: Английский

Процитировано

0
Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential DOI Open Access
László Radnai,

Erica J. Young,

Carlos Kikuti

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Окт. 7, 2024

ABSTRACT Non-muscle myosin II (NMII), a molecular motor that regulates critical processes such as cytokinesis and neuronal synaptic plasticity, has substantial therapeutic potential. However, translating this potential to in vivo use been hampered by the lack of selective tools. The most prototypical non-selective inhibitor, blebbistatin inactivates both NMII cardiac (CMII), key regulator heart function. Using rational drug design, we developed series inhibitors improve tolerability selectively targeting over CMII, including MT-228, which excellent properties high brain penetration efficacy preclinical models stimulant disorder, no current FDA-approved therapies. structure MT-228 bound provides insight into its 17-fold selectivity for CMII. MT-228’s broad window opens door new disease treatments valuable tools scientific community, along with promising leads future medication development. Highlights Research suggests numerous indications, from axon regeneration cancer, would benefit small molecule inhibitor non-muscle II, actin cytoskeleton. Current chemical probe options are very limited sufficient safety studies, show is primarily due potent inhibition II. Rational design focused on improving target pan-myosin blebbistatin, led identification wide window. High-resolution reveals results different positioning compared an important sequence difference between binding pocket. A single administration shows long-lasting animal unmet rapidly escalating need treatments.

Язык: Английский

Процитировано

0
Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal DOI Creative Commons
Ty S. Schepis

Addiction, Год журнала: 2024, Номер unknown

Опубликована: Дек. 10, 2024

While awaiting randomized controlled trial results, analyses of electronic heath record data can further our understanding the effectiveness glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists for substance use disorders without medication treatment options, such as cannabis stimulant disorders. Many efficacious behavioral treatments exist (SUDs), but these often have important limitations. Behavioral options that include cognitive–behavioral therapy contingency management effectively treat a variety SUDs [1, 2], interventions are limited by their expense, availability trained clinicians motivation time commitment required those seeking [3, 4]. SUD medications similarly impacted access, cost motivational barriers [3], with structural in some countries [5, 6] resulting from unique concerns about potential misuse or diversion highly effective opioid agonist [7]. Along limitations, many individuals may not benefit specific treatment, highlighting need ongoing development. Qeadan et al. [8] provide intriguing evidence linked to reduced incidence alcohol intoxication overdose disorder disorder, respectively. Using health (EHR) US sample, they found 50% reduction medical visits 40% overdose. When combined animal [9] emerging more mixed human experimental observational studies [10-12], al.'s methodological perspective strengthens case double-blind, trials (RCTs) evaluate SUD. Indeed, diverse sets methodologies samples support GIP GLP-1 increase RCTs, addictions research needs perspectives truly understand causes develop Medication alcohol, nicotine/tobacco dependence be reasons noted above, at least exist. This is disorders, where no approved available [13-15]. Thus, clear direction future test efficacy psychostimulant ultimate standard will double-blind researchers should also consider using administrative outcomes Together re-analysis existing study data, rapid evaluation EHR motivate inform design RCTs ultimately determine utility cannabis, other SUDs. In addition evaluations GIP-1 offer rich opportunity reuse past, only very perceptive could identify promising repurposing SUD, exponential increases computing power newer machine-learning artificial intelligence methods, opportunities large-scale exploratory investigations candidates later hypothesis-driven evaluation. Ultimately, caution needed when approaching Leggio [16] highlighted. Regulatory approval necessary step before any [16], meantime investigate exploration large therapies move forward advance scope Ty S. Schepis: Conceptualization; funding acquisition; writing - original draft. article was funded Department Health Human Services, National Institutes Health, Institute on Drug Abuse (R01DA043691). T.S.S. receives Abuse, Substance Mental Services Administration Food Administration.

Язык: Английский

Процитировано

0